Neoadjuvant chemo shows mixed results in PCa

San Francisco--Continuing a trend of mixed results seen in previousstudies, neoadjuvant chemotherapy with docetaxel (Taxotere) resulted ina significant PSA response but failed to induce any histologic changes inlocally advanced prostate cancer, Cleveland Clinic investigators reportedat the AUA annual meeting.

Related Videos

Related Content

Advertisement

October 16th 2024

Is video-based research feasible for pediatric urology visits?

Francesca A. Williamson, PhD Pankaj P. Dangle, MD, MCh, FAAP

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.

September 8th 2020

Speaking of Urology: Dr. Finkelstein discusses telemedicine for pediatric post-op visits

Urology Times staff

In this episode, Julia Beth Finkelstein, MD, MPH, CPPS, discusses what she and her co-authors learned from a recent study evaluating the use of telemedicine for pediatric post-op visits.

August 17th 2024

Amanda J. Saraf, DO, shares ongoing research on oncofertility options for pediatric patients

Urology Times staff

"But here at IU, we have an experimental protocol that's open that's called testicular tissue cryopreservation, and it's a collaboration with UPMC," says Amanda J. Saraf, DO.

July 16th 2024

ER utilization and overtreatment for UTI in pediatric patients with spina bifida

Urology Times staff

"We've been working with families and other providers to learn the diagnostic criteria for what makes a urinary tract infection and to avoid treating when it's unnecessary," says Briony K. Varda, MD, MPH.

February 15th 2024

Dr. Laurence Baskin discusses robotic pediatric urological surgery at UCSF

Laurence Baskin, MD

"Robotic surgery has some major advantages. One that rises to the top is that your magnification is anywhere from 10x-15x higher," according to Laurence S. Baskin, MD.

April 1st 2021

Pivotal data for lumasiran in PH1 published in NEJM

Jason M. Broderick

The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.

Related Content

Advertisement

October 16th 2024

Is video-based research feasible for pediatric urology visits?

Francesca A. Williamson, PhD Pankaj P. Dangle, MD, MCh, FAAP

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.

September 8th 2020

Speaking of Urology: Dr. Finkelstein discusses telemedicine for pediatric post-op visits

Urology Times staff

In this episode, Julia Beth Finkelstein, MD, MPH, CPPS, discusses what she and her co-authors learned from a recent study evaluating the use of telemedicine for pediatric post-op visits.

August 17th 2024

Amanda J. Saraf, DO, shares ongoing research on oncofertility options for pediatric patients

Urology Times staff

"But here at IU, we have an experimental protocol that's open that's called testicular tissue cryopreservation, and it's a collaboration with UPMC," says Amanda J. Saraf, DO.

July 16th 2024

ER utilization and overtreatment for UTI in pediatric patients with spina bifida

Urology Times staff

"We've been working with families and other providers to learn the diagnostic criteria for what makes a urinary tract infection and to avoid treating when it's unnecessary," says Briony K. Varda, MD, MPH.

February 15th 2024

Dr. Laurence Baskin discusses robotic pediatric urological surgery at UCSF

Laurence Baskin, MD

"Robotic surgery has some major advantages. One that rises to the top is that your magnification is anywhere from 10x-15x higher," according to Laurence S. Baskin, MD.

April 1st 2021

Pivotal data for lumasiran in PH1 published in NEJM

Jason M. Broderick

The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.